US2005282799A1PendingUtilityA1

Method of treating lower urinary tract disorders

Assignee: DYNOGEN INCPriority: Apr 4, 2003Filed: May 6, 2005Published: Dec 22, 2005
Est. expiryApr 4, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61P 13/10A61K 31/5513A61K 31/551A61P 13/02A61P 13/08A61K 31/519A61K 31/00A61K 45/06
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT 3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT 3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

Claims

exact text as granted — not AI-modified
1 - 70 . (canceled)  
     
     
         71 . Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of urinary incontinence.  
     
     
         72 . Use according to  claim 71 , wherein the salt is the monohydrate hydrochloride.  
     
     
         73 . Use according to  claim 71  or  claim 72 , wherein the urinary incontinence is stress urinary incontinence.  
     
     
         74 . A method for the treatment of urinary incontinence in a patient suffering therefrom, comprising administering to the patient an effective amount of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.  
     
     
         75 . The method according to  claim 74 , wherein the salt is the monohydrate hydrochloride.  
     
     
         76 . The method according to  claim 74  or  claim 75 , wherein the urinary incontinence is stress urinary incontinence.

Join the waitlist — get patent alerts

Track US2005282799A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.